The Global Active
Implantable Medical Devices Market by product type (pacemaker, implantable
cardioverter defibrillator, cardiac resynchronization therapy devices,
neurostimulator, drug infusion pump, implantable loop recorder, cochlear
implant, and others), and region (North America, Latin America, Europe, Asia
Pacific, the Middle East, and Africa) was valued at US$ 16,721.2 million in
2016 and is projected to exhibit a CAGR of 5.4% over the forecast period
(2017–2025).
Advancements in technology in
active implantable medical devices such as MRI compatible pacemakers and
cochlear implants with smartphone connectivity are being developed by key
players in the market, which is expected to be a major driving factor
propelling demand for active implantable medical devices over the forecast
period. Manufacturers are focusing on upgrading the available implantable
medical devices as well as developing new devices for various acute conditions
related to diseases such as cardiovascular and neurological. In 2016, Medtronic
Plc. was the first company to receive the U.S. Food & Drug Administration
(FDA) approval for leadless pacemaker, Micra. Micra transcatheter pacing system
(TPS) is 93% smaller than conventional pacemakers and Micra is directly placed
in heart for monitoring the heart rate. Furthermore, in 2016, Boston Scientific
Corporation was successful in receiving approval for its EMBLEM MRI
subcutaneous implantable cardioverter defibrillator (ICD) system. Biotronik
received approval for its leadless ICD system, which is first of its kind, in
the U.S. in July 2017. Moreover, in 2016, Medtronic plc was the first company
to receive FDA approval for magnetic resonance imaging (MRI) conditional
cardiac resynchronization therapy devices (CRT-D), and was also successful in
receiving approval from FDA for MR-Conditional Quadripolar CRT-P in May 2017.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1126
In 2016, St. Jude Medical
launched its first commercial implants of dorsal root ganglion (DRG)
stimulation therapy for management of chronic intractable pain in the U.S.
Furthermore, Cochlear Limited launched iPhone compatible cochlear implant in
July 2017. Abbott announced European CE mark approval for world’s first
smartphone compatible Confirm Rx insertable cardiac monitor in October 2017.
Browse 30 Market Data Tables and
56 Figures spread through 197 Pages and in-depth TOC on Active Implantable
Medical Devices Market by Product Type (pacemaker, implantable cardioverter
defibrillator, cardiac resynchronization therapy devices, neurostimulator, drug
infusion pump, implantable loop recorder, cochlear implant, and others), and
Region (North America, Latin America, Europe, Asia-Pacific, the Middle East, and,
Africa) - Global Forecast to 2025
Manufacturers are increasing
investment in developing advanced implantable medical devices to monitor vital
organs and capability of their functioning. Medtronic plc received the U.S. FDA
approval for its portfolio of Azure pacemakers with BlueSync technology in
November 2017. This technology-enabled secure, automatic, and wireless remote
monitoring via the Medtronic CareLink Network making remote patient monitoring
possible in case of pacemakers. Furthermore, research organizations are
focusing on developing batteryless pacemakers. For instance, researchers from
Rice University and Texas Heart Institute (THI) introduced a wireless, and
batteryless pacemaker that can directly be implanted into a patient’s heart, in
June 2017. Furthermore, Glenfield Hospital, U.K. is focusing on developing a
new technique for fitting pacemakers in patients under HOPE-HF clinical trials,
which involves placing an extra pacemaker wire into the heart to correct delays
in electrical activation. The clinical trials as a part of the His Optimized
Pacing Evaluated for Heart Failure Trial (HOPE-HF) are being conducted
throughout the country.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/active-implantable-medical-devices-market-1126
Key Takeaways of the Active Implantable
Medical Devices Market:
The global active implantable
medical devices market is expected to exhibit a CAGR of 5.4% over the forecast
period (2017–2025), owing to presence of high potential markets, especially in
Asia Pacific, Latin America, Middle East, and Africa. Multiple product launches
from leading players such as Medtronic plc. and St. Jude Medical, Inc and
growing number of innovative start-ups in the field in these regions in recent
years is has led to development of cost-effective products, which in turn has
resulted in higher adoption rate for the technology
Strong competition in the market
spurs the demand for continuous development from supply as well as demand side
as manufacturers thrive to stay competitive in the market and customers remain
on the lookout for the alternatives boosting the development rate in active
implantable medical devices market driving growth of the global active
implantable medical devices market
Implantable Neurostimulators
product type segment is expected to show significant growth owing to increasing
application in management of chronic pain diseases
Asia Pacific region is expected
to show significant growth owing to multiple product launches by major players
such as launch of Edora pacemakers by Biotronik in Japan in 2017
According to WHO, 31% (about 17.7
million) of all global deaths were due to cardiovascular diseases (CVDs) and
this number is expected to grow further as aging population, which are more
prone to CVDs is growing. Growing prevalence of cardiovascular diseases, which
can be monitored or treated by devices such as pacemakers and ICDs, is expected
to be the major factors driving growth of the global active implantable medical
devices market over the forecast period
Major players operating in the
active implantable medical devices market include Cochlear Limited, Boston
Scientific Corporation, Medtronic Plc, LivaNova Plc, Abbott Laboratories,
Sonova Holding AG, William Demant holding A/S, Nurotron Biotechnology Co.,
Ltd., and Med-EL
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1126
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment